US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUROGENE INC

22.64

-0.1350-0.59%

Volume:350.58K

Turnover:7.92M

Market Cap:350.61M

PE:-5.26

High:23.52

Open:22.78

Low:21.88

Close:22.77

52wk High:39.20

52wk Low:6.88

Shares:15.49M

Float Shares:6.02M

Volume Ratio:1.35

T/O Rate:5.83%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.3039

EPS(LYR):-4.2775

ROE:-39.41%

ROA:-25.07%

PB:1.28

PE(LYR):-5.29

Loading ...

Overview Company News Filings

Craig-Hallum Keeps Their Buy Rating on Neurogene (NGNE)

Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data

Neurogene Inc announces Embolden trial for NGN401 gene therapy in Rett syndrome to begin dosing in Q4 2025

Neurogene Announces Positive Regulatory Update for Ngn-401 Gene Therapy in Rett Syndrome With Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

THOMSON REUTERS

Neurogene Inc - Completes Discussions With FDA on Embolden Registrational Trial Protocol

THOMSON REUTERS

Neurogene Insiders Placed Bullish Bets Worth US$1.46m

Simply Wall St.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule

Neurogene Inc. Announces New Inducement Stock Option Grants for Employees Under 2025 Compensation Plan

Neurogene Inc. Announces Inducement Grants for New Employees Under 2025 Plan

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. -- Barrons.com

Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary

Neurogene Inc. Unveils Presentation on Promising Advances in Genetic Medicines for Rare Neurological Diseases

Neurogene Q2 EPS $(1.05) Beats $(1.16) Estimate

BRIEF-Neurogene Q2 Net Income USD -22.016 Million

Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates

THOMSON REUTERS

Neurogene Inc: Cash Runway Into Early 2028

THOMSON REUTERS

Neurogene Q2 Basic EPS USD -1.05

THOMSON REUTERS

Neurogene Q2 Operating Income USD -26.081 Million

THOMSON REUTERS

Neurogene Inc. Reports Q2 2025 Financials: Net Loss Widens to $22M as R&D Expenses Surge

BRIEF-Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NGNE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGNE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":22.635,"timestamp":1763412539608,"preClose":22.77,"halted":0,"volume":350580,"delay":0,"floatShares":6017500,"shares":15489800,"eps":-4.303895,"marketStatus":"Trading","change":-0.135,"latestTime":"11-17 15:49:09 EST","open":22.78,"high":23.5199,"low":21.88,"amount":7915456.591500001,"amplitude":0.07202,"askPrice":22.65,"askSize":408,"bidPrice":22.62,"bidSize":293,"shortable":0,"etf":0,"ttmEps":-4.303895,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1763413200000},"marketStatusCode":2,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":22.77,"preHourTrading":{"tag":"盘前","latestPrice":22.77,"preClose":22.77,"latestTime":"08:54 EST","volume":3,"amount":68.31,"timestamp":1763387677587},"postHourTrading":{"tag":"盘后","latestPrice":22.77,"preClose":22.77,"latestTime":"19:22 EST","volume":1209,"amount":27529.38,"timestamp":1763166120280},"volumeRatio":1.352055,"impliedVol":1.2365,"impliedVolPercentile":0.684},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","floatShares":6017500,"roa":"-25.07%","roe":"-39.41%","lyrEps":-4.277545,"volumeRatio":1.352055,"shares":15489800,"dividePrice":0,"high":23.5199,"amplitude":0.07202,"preClose":22.77,"low":21.88,"week52Low":6.875,"pbRate":"1.28","week52High":39.2,"institutionHeld":0,"latestPrice":22.635,"committee":-0.164051,"eps":-4.303895,"divideRate":0,"volume":350580,"delay":0,"ttmEps":-4.303895,"open":22.78,"prevYearClose":22.86,"prevWeekClose":22.77,"prevMonthClose":34.26,"prevQuarterClose":17.33,"fiveDayClose":28.3,"twentyDayClose":32.16,"sixtyDayClose":19.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGNE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"NGNE","fiscalQuarterEnding":"2025/09","expectedEps":-1.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.99},{"market":"US","date":"2025-08-11","symbol":"NGNE","fiscalQuarterEnding":"2025/06","expectedEps":-1.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-1.05},{"market":"US","date":"2025-05-09","symbol":"NGNE","fiscalQuarterEnding":"2025/03","expectedEps":-1.05,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-03-24","symbol":"NGNE","fiscalQuarterEnding":"2024/12","expectedEps":-1.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.99},{"market":"US","date":"2024-11-18","symbol":"NGNE","fiscalQuarterEnding":"2024/09","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731906000000,"reportTimeType":"post","actualEps":-1.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGNE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGNE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1750309200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGNE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGNE","date":"2025-11-14","current":-5.25919,"percent":0.599119,"low":-19.523035,"twenty":-11.286405,"median":-6.13229,"eighty":-3.416049,"high":-1.458307,"avg":-7.256923,"sd":4.054301,"marketCap":410324802},"quantilePoints":[{"date":"2023-12-29","current":-4.323556,"twenty":-4.185645,"median":-3.978778,"eighty":-3.916869,"marketCap":220311097},{"date":"2024-01-05","current":-5.423319,"twenty":-5.000527,"median":-4.624292,"eighty":-3.978778,"marketCap":276350648},{"date":"2024-01-12","current":-8.005373,"twenty":-7.157271,"median":-5.423319,"eighty":-4.323556,"marketCap":407921769},{"date":"2024-01-19","current":-7.59768,"twenty":-7.599292,"median":-7.086806,"eighty":-4.804734,"marketCap":387147382},{"date":"2024-01-26","current":-8.053188,"twenty":-7.611677,"median":-7.561189,"eighty":-4.985427,"marketCap":410358272},{"date":"2024-02-02","current":-7.741127,"twenty":-7.937424,"median":-7.577547,"eighty":-5.338761,"marketCap":394456888},{"date":"2024-02-09","current":-7.497015,"twenty":-7.980207,"median":-7.59013,"eighty":-6.388695,"marketCap":382017903},{"date":"2024-02-16","current":-7.549864,"twenty":-7.937424,"median":-7.577547,"eighty":-6.995453,"marketCap":384710880},{"date":"2024-02-23","current":-7.622846,"twenty":-7.894138,"median":-7.57503,"eighty":-7.129085,"marketCap":388429751},{"date":"2024-03-01","current":-7.819143,"twenty":-7.894138,"median":-7.588872,"eighty":-7.262969,"marketCap":398432234},{"date":"2024-03-08","current":-9.734292,"twenty":-8.024499,"median":-7.59768,"eighty":-7.381754,"marketCap":496020561},{"date":"2024-03-15","current":-8.697444,"twenty":-8.083388,"median":-7.629138,"eighty":-7.463796,"marketCap":443186933},{"date":"2024-03-22","current":-17.419498,"twenty":-9.10262,"median":-7.660596,"eighty":-7.498525,"marketCap":632623921},{"date":"2024-03-28","current":-17.433655,"twenty":-9.373408,"median":-7.741127,"eighty":-7.499532,"marketCap":633138041},{"date":"2024-04-05","current":-15.090764,"twenty":-9.721205,"median":-7.845567,"eighty":-7.510605,"marketCap":548051280},{"date":"2024-04-12","current":-13.565408,"twenty":-14.180505,"median":-7.97769,"eighty":-7.536275,"marketCap":492654915},{"date":"2024-04-19","current":-11.176509,"twenty":-13.912948,"median":-8.029281,"eighty":-7.549864,"marketCap":405897266},{"date":"2024-04-26","current":-10.571321,"twenty":-13.650346,"median":-8.053188,"eighty":-7.549864,"marketCap":383918661},{"date":"2024-05-03","current":-12.537284,"twenty":-13.442874,"median":-8.146303,"eighty":-7.558924,"marketCap":455316556},{"date":"2024-05-10","current":-11.764996,"twenty":-13.2542,"median":-9.074937,"eighty":-7.57352,"marketCap":427269365},{"date":"2024-05-17","current":-10.587696,"twenty":-13.13876,"median":-9.272492,"eighty":-7.576037,"marketCap":433830864},{"date":"2024-05-24","current":-9.887502,"twenty":-12.800854,"median":-9.44488,"eighty":-7.581574,"marketCap":405140389},{"date":"2024-05-31","current":-10.685033,"twenty":-12.52136,"median":-9.620612,"eighty":-7.588117,"marketCap":437819226},{"date":"2024-06-07","current":-11.771752,"twenty":-12.409114,"median":-9.810897,"eighty":-7.59013,"marketCap":482347539},{"date":"2024-06-14","current":-13.301826,"twenty":-12.457666,"median":-9.93146,"eighty":-7.59013,"marketCap":545042335},{"date":"2024-06-21","current":-9.842528,"twenty":-12.564112,"median":-9.93146,"eighty":-7.59617,"marketCap":403297579},{"date":"2024-06-28","current":-11.030474,"twenty":-12.52136,"median":-10.019377,"eighty":-7.599292,"marketCap":451973662},{"date":"2024-07-05","current":-11.397945,"twenty":-12.537284,"median":-10.188931,"eighty":-7.605739,"marketCap":467030798},{"date":"2024-07-12","current":-13.232134,"twenty":-12.537284,"median":-10.458961,"eighty":-7.622846,"marketCap":542186671},{"date":"2024-07-15","current":-13.48873,"twenty":-12.644595,"median":-10.463671,"eighty":-7.625363,"marketCap":552700705},{"date":"2024-08-02","current":-12.832984,"twenty":-12.76836,"median":-10.468381,"eighty":-7.627879,"marketCap":525831507},{"date":"2024-08-09","current":-11.578513,"twenty":-12.617767,"median":-10.579508,"eighty":-7.644992,"marketCap":474429562},{"date":"2024-08-16","current":-9.721942,"twenty":-12.533918,"median":-10.468381,"eighty":-7.659841,"marketCap":462832495},{"date":"2024-08-23","current":-9.22793,"twenty":-12.500388,"median":-10.20777,"eighty":-7.686769,"marketCap":439314055},{"date":"2024-08-30","current":-9.934831,"twenty":-12.3607,"median":-10.082175,"eighty":-7.732068,"marketCap":472967513},{"date":"2024-09-06","current":-9.383503,"twenty":-12.215183,"median":-10.030358,"eighty":-7.751697,"marketCap":446720414},{"date":"2024-09-13","current":-11.015654,"twenty":-12.198503,"median":-10.056266,"eighty":-7.799009,"marketCap":524422220},{"date":"2024-09-20","current":-11.343175,"twenty":-12.111032,"median":-10.20463,"eighty":-7.829713,"marketCap":540014556},{"date":"2024-09-27","current":-10.69359,"twenty":-12.018852,"median":-10.282823,"eighty":-7.883065,"marketCap":509089757},{"date":"2024-10-04","current":-12.12104,"twenty":-12.018852,"median":-10.468381,"eighty":-7.937424,"marketCap":577046353},{"date":"2024-10-11","current":-13.141817,"twenty":-12.215183,"median":-10.579508,"eighty":-7.980207,"marketCap":625642465},{"date":"2024-10-18","current":-14.443716,"twenty":-12.644595,"median":-10.678753,"eighty":-7.993293,"marketCap":687621999},{"date":"2024-10-25","current":-13.155463,"twenty":-12.975228,"median":-10.69616,"eighty":-8.014936,"marketCap":626292146},{"date":"2024-10-31","current":-11.938174,"twenty":-12.976568,"median":-10.764003,"eighty":-8.053188,"marketCap":568340632},{"date":"2024-11-08","current":-18.968977,"twenty":-13.201862,"median":-10.833215,"eighty":-8.053188,"marketCap":903056103},{"date":"2024-11-15","current":-10.699049,"twenty":-13.232134,"median":-10.867118,"eighty":-8.053188,"marketCap":509349629},{"date":"2024-11-22","current":-3.804354,"twenty":-13.201862,"median":-10.811892,"eighty":-8.005373,"marketCap":202570426},{"date":"2024-11-29","current":-7.081932,"twenty":-13.164743,"median":-10.73726,"eighty":-7.916284,"marketCap":377091628},{"date":"2024-12-06","current":-6.123936,"twenty":-13.144546,"median":-10.69616,"eighty":-7.738107,"marketCap":326081199},{"date":"2024-12-13","current":-6.220014,"twenty":-13.009618,"median":-10.678753,"eighty":-7.632912,"marketCap":331197071},{"date":"2024-12-20","current":-6.147607,"twenty":-12.971208,"median":-10.579508,"eighty":-7.59013,"marketCap":327341631},{"date":"2024-12-27","current":-6.711544,"twenty":-12.908645,"median":-10.50763,"eighty":-7.57654,"marketCap":357369573},{"date":"2025-01-03","current":-6.374574,"twenty":-12.853892,"median":-10.405691,"eighty":-7.549864,"marketCap":339426951},{"date":"2025-01-10","current":-5.995231,"twenty":-12.800672,"median":-10.212067,"eighty":-7.505069,"marketCap":319228040},{"date":"2025-01-17","current":-4.918377,"twenty":-12.651961,"median":-10.173232,"eighty":-7.427764,"marketCap":261888801},{"date":"2025-01-24","current":-4.346472,"twenty":-12.574112,"median":-10.030358,"eighty":-7.086806,"marketCap":231436615},{"date":"2025-01-31","current":-4.332524,"twenty":-12.537284,"median":-9.920586,"eighty":-6.842433,"marketCap":230693879},{"date":"2025-02-07","current":-6.50018,"twenty":-12.535901,"median":-9.842528,"eighty":-6.605719,"marketCap":346115092},{"date":"2025-02-14","current":-5.236411,"twenty":-12.52887,"median":-9.777894,"eighty":-6.491539,"marketCap":278823188},{"date":"2025-02-21","current":-4.829104,"twenty":-12.471907,"median":-9.750601,"eighty":-6.430271,"marketCap":257135289},{"date":"2025-02-28","current":-4.770518,"twenty":-12.349943,"median":-9.721942,"eighty":-6.303838,"marketCap":254015797},{"date":"2025-03-07","current":-4.672876,"twenty":-12.236804,"median":-9.661093,"eighty":-6.2189,"marketCap":248816643},{"date":"2025-03-14","current":-4.686825,"twenty":-12.214976,"median":-9.588204,"eighty":-6.130619,"marketCap":249559380},{"date":"2025-03-21","current":-4.24883,"twenty":-12.149292,"median":-9.555425,"eighty":-6.004158,"marketCap":226237461},{"date":"2025-03-28","current":-3.045755,"twenty":-12.12341,"median":-9.468113,"eighty":-5.45457,"marketCap":228870246},{"date":"2025-04-04","current":-1.92123,"twenty":-12.043093,"median":-9.418302,"eighty":-5.225252,"marketCap":144368903},{"date":"2025-04-11","current":-1.782154,"twenty":-12.004592,"median":-9.374415,"eighty":-5.034123,"marketCap":133918207},{"date":"2025-04-17","current":-2.044108,"twenty":-11.997937,"median":-9.328916,"eighty":-4.961897,"marketCap":153602450},{"date":"2025-04-25","current":-2.917172,"twenty":-11.976697,"median":-9.167755,"eighty":-4.922368,"marketCap":219207954},{"date":"2025-05-02","current":-2.922866,"twenty":-11.956745,"median":-9.074937,"eighty":-4.83359,"marketCap":219635816},{"date":"2025-05-09","current":-2.846947,"twenty":-11.943832,"median":-8.430682,"eighty":-4.764939,"marketCap":213930990},{"date":"2025-05-16","current":-3.416053,"twenty":-11.921952,"median":-8.053188,"eighty":-4.703006,"marketCap":276256218},{"date":"2025-05-23","current":-3.181497,"twenty":-11.907794,"median":-8.053188,"eighty":-4.667296,"marketCap":257287670},{"date":"2025-05-30","current":-3.304948,"twenty":-11.891321,"median":-7.997823,"eighty":-4.63103,"marketCap":267271116},{"date":"2025-06-06","current":-4.042124,"twenty":-11.854896,"median":-7.927357,"eighty":-4.432955,"marketCap":326886552},{"date":"2025-06-13","current":-3.597702,"twenty":-11.83216,"median":-7.80656,"eighty":-4.329176,"marketCap":290946146},{"date":"2025-06-20","current":-3.22735,"twenty":-11.824338,"median":-7.733577,"eighty":-4.305184,"marketCap":260995807},{"date":"2025-06-27","current":-2.922251,"twenty":-11.790759,"median":-7.659337,"eighty":-4.202034,"marketCap":236322433},{"date":"2025-07-03","current":-3.543031,"twenty":-11.778088,"median":-7.622846,"eighty":-3.964273,"marketCap":286524905},{"date":"2025-07-11","current":-3.87282,"twenty":-11.778088,"median":-7.593905,"eighty":-3.821676,"marketCap":313194969},{"date":"2025-07-18","current":-3.985689,"twenty":-11.771752,"median":-7.587614,"eighty":-3.805804,"marketCap":322322691},{"date":"2025-07-25","current":-4.022724,"twenty":-11.764996,"median":-7.573772,"eighty":-3.819913,"marketCap":325317725},{"date":"2025-08-01","current":-3.839312,"twenty":-11.670697,"median":-7.549864,"eighty":-3.819913,"marketCap":310485176},{"date":"2025-08-08","current":-3.784641,"twenty":-11.657709,"median":-7.513374,"eighty":-3.804354,"marketCap":306063936},{"date":"2025-08-15","current":-3.416033,"twenty":-11.655175,"median":-7.497015,"eighty":-3.77935,"marketCap":288292703},{"date":"2025-08-22","current":-3.339933,"twenty":-11.654541,"median":-7.373701,"eighty":-3.740907,"marketCap":281870341},{"date":"2025-08-29","current":-3.186043,"twenty":-11.623292,"median":-7.086806,"eighty":-3.597702,"marketCap":268882897},{"date":"2025-09-05","current":-3.316258,"twenty":-11.587469,"median":-7.081932,"eighty":-3.564545,"marketCap":279872272},{"date":"2025-09-12","current":-3.39574,"twenty":-11.537964,"median":-6.776988,"eighty":-3.481558,"marketCap":286580073},{"date":"2025-09-19","current":-3.158985,"twenty":-11.502485,"median":-6.605719,"eighty":-3.434395,"marketCap":266599390},{"date":"2025-09-26","current":-2.943369,"twenty":-11.461109,"median":-6.573692,"eighty":-3.385336,"marketCap":248402697},{"date":"2025-10-03","current":-3.547939,"twenty":-11.450166,"median":-6.491539,"eighty":-3.377814,"marketCap":299424797},{"date":"2025-10-10","current":-5.337129,"twenty":-11.445253,"median":-6.449765,"eighty":-3.380182,"marketCap":450421668},{"date":"2025-10-17","current":-5.748068,"twenty":-11.407188,"median":-6.374574,"eighty":-3.383551,"marketCap":485102424},{"date":"2025-10-24","current":-4.855164,"twenty":-11.397945,"median":-6.302167,"eighty":-3.385336,"marketCap":409746708},{"date":"2025-10-31","current":-5.604324,"twenty":-11.395615,"median":-6.221406,"eighty":-3.393711,"marketCap":472971296},{"date":"2025-11-07","current":-4.508487,"twenty":-11.353547,"median":-6.20957,"eighty":-3.411974,"marketCap":380489280},{"date":"2025-11-14","current":-4.862014,"twenty":-11.286405,"median":-6.13229,"eighty":-3.416049,"marketCap":410324802}],"updateTime":1763412549932},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGNE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574686121","title":"Craig-Hallum Keeps Their Buy Rating on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2574686121","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574686121?lang=en_us&edition=fundamental","pubTime":"2025-10-09 21:15","pubTimestamp":1760015743,"startTime":"0","endTime":"0","summary":"In a report released today, Ryan Sigdahl from Craig-Hallum maintained a Buy rating on Neurogene. The company’s shares closed yesterday at $25.83. A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-keeps-their-buy-rating-on-neurogene-ngne-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-keeps-their-buy-rating-on-neurogene-ngne-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE"],"gpt_icon":0},{"id":"2574159455","title":"Neurogene completes FDA discussion on Embolden trial, announces NGN-401 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2574159455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574159455?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:20","pubTimestamp":1760008848,"startTime":"0","endTime":"0","summary":"Neurogene (NGNE) announced the company has completed discussions with the FDA on its Embolden registrational trial protocol and plans to initiate d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-completes-fda-discussion-on-embolden-trial-announces-ngn-401-data-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-completes-fda-discussion-on-embolden-trial-announces-ngn-401-data-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2574156910","title":"Neurogene Inc announces Embolden trial for NGN401 gene therapy in Rett syndrome to begin dosing in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574156910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574156910?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:00","pubTimestamp":1760007646,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on October 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL5cYt63:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2574976156","title":"Neurogene Announces Positive Regulatory Update for Ngn-401 Gene Therapy in Rett Syndrome With Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574976156","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574976156?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:00","pubTimestamp":1760007601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nTUA8BGLJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2574315625","title":"Neurogene Inc - Completes Discussions With FDA on Embolden Registrational Trial Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2574315625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574315625?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:00","pubTimestamp":1760007601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nTUA8BGLJV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2573648316","title":"Neurogene Insiders Placed Bullish Bets Worth US$1.46m","url":"https://stock-news.laohu8.com/highlight/detail?id=2573648316","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573648316?lang=en_us&edition=fundamental","pubTime":"2025-10-05 20:29","pubTimestamp":1759667347,"startTime":"0","endTime":"0","summary":"Over the last year, a good number of insiders have significantly increased their holdings in Neurogene Inc...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ngne/neurogene/news/neurogene-insiders-placed-bullish-bets-worth-us146m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ngne/neurogene/news/neurogene-insiders-placed-bullish-bets-worth-us146m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NGNE","BK4112","BK4139"],"gpt_icon":1},{"id":"2572328633","title":"Neurogene Announces Inducement Grants Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2572328633","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572328633?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:10","pubTimestamp":1759522226,"startTime":"0","endTime":"0","summary":"Oct 3 (Reuters) - Neurogene Inc ::*NEUROGENE ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-OCT-202520:01:00.16 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nRSD5PCpbq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2572638798","title":"Neurogene Inc. Announces New Inducement Stock Option Grants for Employees Under 2025 Compensation Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2572638798","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572638798?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:01","pubTimestamp":1759521672,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has announced the approval of stock option grants for four new employees, totaling 9,390 shares of the company's common stock. The options were granted under Neurogene's 2025 Inducement Plan and will have an exercise price based on the closing price of the company's shares on the grant date, October 1, 2025. The options will vest over four years, with 25% vesting after the first year and the remainder vesting in equal portions quarterly over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on October 03, 2025, and is solely responsible for the information contained","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL6wC9TL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2565959803","title":"Neurogene Inc. Announces Inducement Grants for New Employees Under 2025 Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2565959803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565959803?lang=en_us&edition=fundamental","pubTime":"2025-09-06 04:01","pubTimestamp":1757102475,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has announced the approval of non-qualified stock options for six new employees as part of its 2025 Inducement Plan. The approved Inducement Grants, totaling 47,040 shares of common stock, were granted with an exercise price set to the closing price on September 3, 2025. These options will vest over a four-year period, with an initial 25% vesting on the first anniversary of the commencement date, followed by equal portions every three months over the subsequent 36 months, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on September 05, 2025, and is solely responsible for the information con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL3bYcLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2560210780","title":"Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2560210780","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560210780?lang=en_us&edition=fundamental","pubTime":"2025-08-20 23:02","pubTimestamp":1755702120,"startTime":"0","endTime":"0","summary":"The biotech Rocket Pharmaceuticals said the Food and Drug Administration would allow it to continue a gene therapy trial the agency had put on hold in late May, when a patient in the trial died.Shares of the biotech surged 20% on Wednesday. Even after that run-up, the stock price remains about 45% below where it was trading before the company disclosed the patient death earlier this year.In the following months, investor enthusiasm for gene therapies waned even further, as what was once the biggest idea in biotech delivered even more disappointments and safety worries.The past 12 months have been perhaps the worst yet for the gene therapy field, with multiple patient deaths and sinking share prices. Other high-profile patient deaths have included one in a trial of a Neurogene gene therapy for Rett Syndrome last year, and three patients who received gene therapies made by Sarepta","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","BK4139","IE00B2B36J28.USD","IE00BJT1NW94.SGD","NGNE","BK4585","IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","RCKT","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2558698773","title":"Neurogene Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2558698773","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558698773?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:45","pubTimestamp":1754945101,"startTime":"0","endTime":"0","summary":"Neurogene Inc reports results for the quarter ended June 30 - Earnings SummaryNeurogene Inc NGNE.OQ reported a quarterly adjusted loss of $1.05 per share for the quarter ended June 30, higher than the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nL8N3U31I2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2558698579","title":"Neurogene Inc. Unveils Presentation on Promising Advances in Genetic Medicines for Rare Neurological Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2558698579","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558698579?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:24","pubTimestamp":1754943874,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has presented its August 2025 corporate presentation highlighting advancements in their genetic medicine programs for rare neurological diseases. The company showcased promising interim clinical data for its lead program, NGN-401, aimed at treating Rett syndrome. Start-up activities for the registrational trial of NGN-401 are underway, utilizing Neurogene's proprietary EXACT transgene regulation technology. The presentation also highlighted Neurogene's internal manufacturing capabilities, which provide strategic flexibility and extend the cash runway to fund operations into early 2028. The facilities in Houston support commercial-grade manufacturing, offering the flexibility to manufacture AAV products at low cost. Neurogene's clinical-stage pipeline includes NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten Disease, with additional interim data expected in the second half of 2025. You can access the full presentation through the link below.Disclaimer: This news brie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL2chN9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2558698342","title":"Neurogene Q2 EPS $(1.05) Beats $(1.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558698342","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558698342?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:22","pubTimestamp":1754943754,"startTime":"0","endTime":"0","summary":"Neurogene Q2 EPS $(1.05) Beats $(1.16) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47044316/neurogene-q2-eps-1-05-beats-1-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurogene Q2 EPS $(1.05) Beats $(1.16) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE"],"gpt_icon":0},{"id":"2558660229","title":"BRIEF-Neurogene Q2 Net Income USD -22.016 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2558660229","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558660229?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:10","pubTimestamp":1754943045,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Q2 Net Income USD -22.016 Million\n\n\nAug 11 (Reuters) - Neurogene Q2 operating expenses USD 26.081 million.\n\nQ2 operating income USD -26.081 million\nQ2 basic EPS USD -1.05","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nPLXC645C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2558785660","title":"Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2558785660","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558785660?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:10","pubTimestamp":1754943000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUA2T4XN5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2558666078","title":"Neurogene Inc: Cash Runway Into Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2558666078","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558666078?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:10","pubTimestamp":1754943000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUA2T4XN5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2558660207","title":"Neurogene Q2 Basic EPS USD -1.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2558660207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558660207?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:10","pubTimestamp":1754943000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nPLXC645C8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2558607886","title":"Neurogene Q2 Operating Income USD -26.081 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2558607886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558607886?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:10","pubTimestamp":1754943000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nPLXC645C8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2558602426","title":"Neurogene Inc. Reports Q2 2025 Financials: Net Loss Widens to $22M as R&D Expenses Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2558602426","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558602426?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:09","pubTimestamp":1754942983,"startTime":"0","endTime":"0","summary":"Neurogene Inc.  has announced its financial results for the second quarter of 2025, reporting a net loss of $22.0 million compared to a net loss of $18.5 million for the same period in 2024. Research and Development (R&D) expenses increased to $19.4 million from $15.7 million in the previous year, primarily due to higher costs associated with the Rett syndrome clinical trial and an increase in R&D headcount. General and Administrative (G&A) expenses also rose to $6.7 million from $5.3 million, driven by increased employee-related expenses, including stock-based compensation and headcount. Significant operational updates include the announcement of the Embolden registrational clinical trial design for NGN-401 gene therapy for Rett syndrome, with initiation activities underway. Additionally, Neurogene has completed dosing in the Phase 1/2 NGN-401 trial and is on track to report updated clinical efficacy and safety data in the second half of 2025. The company has a cash runway extending i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL8hCjfs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2558577421","title":"BRIEF-Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2558577421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558577421?lang=en_us&edition=fundamental","pubTime":"2025-08-09 06:04","pubTimestamp":1754690676,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Aug 8 (Reuters) - Neurogene Inc NGNE.O:NEUROGENE ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBw4G9xmLaFurther company coverage: NGNE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nTUA4YND2J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}